Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Skin cancer, melanoma
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Results 1-19 of 19 for your search:
Start Over
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 103A-301, NCI-2012-01351, NCT01546571
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CL-CA-P01, NCI-2015-00099, 2014-000544-15, 2015-001984-38, CL-CA-P01-00-US, NCT01875653
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: NWBio 050012, NCI-2013-01301, NCT01882946
Vaccine Therapy and Iscomatrix with or without Cyclophosphamide and Celecoxib in Treating Patients with Thoracic Malignancies or Tumors That Have Spread to the Chest Cavity
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0053, NCI-2014-02465, 140053, P131392, NCT02054104
Trial of pIL-12 Electroporation Malignant Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OMS-I100, NCI-2014-01065, 11854, NCT01502293
INCB024360 and Vaccine Therapy in Treating Patients with Stage III-IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-04, NCI-2013-01605, NCT01961115
Immunotherapy Study for Patients With Stage IV Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NLG0304, NCI-2014-00700, 1303-1217, NCT02054520
CDX-1401 and Poly-ICLC Vaccine Therapy with or without CDX-301in Treating Patients with Stage IIB-IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CITN-07-FLT3L, NCI-2014-00898, NCT02129075
Phase IIB TL + YCWP + DC in Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: WIRB Protocol: 20141932, NCI-2014-02585, NCT02301611
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: 201103308, NCI-2011-00484, 07-0652, NCT00683670
Nivolumab, Vaccine Therapy, and Ipilimumab in Treating Patients with Stage III or Stage IV Melanoma That Has Been Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: MCC-15651, NCI-2011-00737, CDR0000682183, NCI-P8316, P-8316, 8316, NCT01176474
Vaccine Therapy With or Without Recombinant Interferon Alfa-2b in Treating Patients With Recurrent Stage III-IV Melanoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-021, NCI-2013-00388, UPCI 09-021, NCT01622933
Vaccine Therapy in Treating Patients with Advanced Stage III-IV Melanoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 215912, NCI-2012-02231, NCT01744171
Vaccine Therapy in Treating Patients with Stage IV Melanoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-306, NCI-2013-01799, NCT01753089
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: LUD2012-004, NCI-2013-01366, NCT01810016
Vaccine Therapy in Treating Patients with Stage IIIB-IV Melanoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-240, NCI-2014-00958, NCT01970358
A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ID-LV305-2013-001, NCI-2014-01153, NCT02122861
MART-1 Antigen with or without TLR4 Agonist GLA-SE in Treating Patients with Stage II-IV Melanoma That Has Been Removed by Surgery
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1177, NCI-2014-02479, Mod14-002307-06, NCT02320305
Start Over